Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Janssen believes next-gen drug Tremfya can meet unmet needs in psoriasis and beyond

By Brian Buntz | June 21, 2021

Janssen TremfyaTwo decades ago, psoriasis was a poorly understood condition. Treatment options for severe psoriasis included powerful immunosuppressant agents such as methotrexate and cyclosporin that can have significant side effects.

But the fact those immunosuppressant drugs were effective at treating psoriasis helped pave the way to use biologics to treat the condition. The experience “really taught us that psoriasis was an immunologic disease,” said Dr. Lloyd Miller, VP of immunodermatology at Janssen Research & Development (NYSE:JNJ).

After researchers determined that psoriasis, which affects some 125 million patients worldwide, results from excess inflammatory cytokines, drug developers began to test the potential of inhibitors of tumor necrosis factor (TNF) and interleukin 17 (IL-17) in treating the disease.

FDA approved TNF blockers such as Janssen’s Remicade (infliximab) for psoriasis and psoriatic arthritis in the mid-2000s. IL-17A antagonists such as Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Lilly won FDA indications for plaque psoriasis and psoriatic arthritis roughly a decade later.

Now, Janssen is positioning its IL-23 inhibitor Tremfya (guselkumab) as a further evolution. In October 2020, the company announced that Tremfya maintained skin clearance for up to five years in the Phase 3 VOYAGE 1 trial involving adults with moderate to severe plaque psoriasis. The trial marked “the first time that an IL-23 inhibitor therapy demonstrated efficacy and safety through a five-year period of use,” Miller said.

Janssen's Tremfya

Tremfya (guselkumab) won FDA approval for adult patients with active psoriatic arthritis in 2020.

Tremfya is the first approved biologic to selectively inhibit the P-19 subunit of IL-23.

At week 252 in the VOYAGE 1 trial, 84% of Tremfya recipients achieved a Psoriasis Area Severity Index (PASI) 90 response, which indicates a 90% improvement in psoriasis severity and extent compared to baseline. A total of 82.4% achieved a score of 0 or 1 on the five-point Investigator’s Global Assessment (IGA) scale. A ‘0’ indicates clear skin, while a ‘1’ represents almost clear skin.

“We see Tremfya as restoring immune balance rather than immune-suppressing patients,” Miller said.

FDA initially approved the drug for the treatment of moderate to severe plaque psoriasis in 2017.

Moody’s recently cited Tremfya along with AbbVie‘s (NYSE:ABBV) Skyrizi, Novartis’ (NYSE:NVS) Cosentyx and Lilly’s (NYSE:LLY) Taltz as biologics poised for good growth.

Miller said that the growing amount of clinical data involving the use of biologics in psoriasis could pave the way for new treatments for other complex immune-mediated diseases such as atopic dermatitis and hidradenitis suppurativa.

But the efficacy rate of Tremfya in psoriasis and psoriatic arthritis can also help minimize systemic comorbidities such as metabolic syndrome and cardiovascular disease. Patients with psoriasis can suffer from anxiety and social isolation. “Psoriasis itself can be itchy or painful in some patients,” Miller said. “And patients with psoriatic arthritis can be in a lot of pain. So we know that having psoriasis and psoriatic arthritis is associated with a lack of mobility.” That, in turn, can lead to weight gain, which increases the risk for conditions such as obesity and diabetes, which are metabolic diseases associated with more inflammation. “If you think about it, psoriasis affects your entire body — beyond your skin,” Miller said.

Psoriasis can also affect the mind and lead to significant rates of depression. “You also see suicide and alcoholism at higher rates,” Miller said.

Biologics promise to stop the vicious cycle. Drugs like Tremfya are “meeting an unmet need — not just in psoriasis but also in patients who have psoriatic arthritis with joint pain, enthesitis and other arthralgias,” Miller said.

Janssen hopes that the IL-23 inhibitor will offer a similar promise for other conditions. “If you follow the IL-23 pathway, we also know that it is very active in inflammatory bowel disease such as Crohn’s disease and also colitis,” Miler said. “Those trials are ongoing.”

 


Filed Under: clinical trials, Dermatology, Drug Discovery, Rheumatology
Tagged With: guselkumab, IL-23 inhibitor, Janssen, Johnson & Johnson, Tremfya
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE